Abstract
Background The COVID-19 pandemic is affecting all Canadian families, with some impacted differently than others. Our study aims to: 1) determine the prevalence and transmission of SARS-CoV-2 infection among Canadian families, 2) identify predictors of infection susceptibility and severity of SARS-CoV-2 and 3) identify health and psychosocial impacts of the COVID-19 pandemic.
Methods This study builds upon the CHILD Cohort Study, an ongoing multi-ethnic general population prospective cohort consisting of 3454 Canadian families with children born in Vancouver, Edmonton, Manitoba, and Toronto between 2009-12. During the pandemic, 1462 CHILD households (5378 individuals) consented to participate in the CHILD COVID-19 Add-On Study involving: (1) brief biweekly surveys about COVID-19 symptoms and testing; (2) quarterly questionnaires assessing COVID-19 exposure, testing and vaccination status, physical and mental health, and pandemic-driven life changes; (3) in-home biological sampling kits to collect blood and stool. Mean ages were 9 years (range 0-17) for children and 43 years (range 18-85) for adults. Prevalence of SARS-CoV-2 infection will be estimated from survey data and confirmed through serology testing. We will combine these new data with a wealth of pre-pandemic CHILD data and use multivariate modelling and machine learning methods to identify risk and resilience factors for susceptibility and severity to the direct and indirect effects of the pandemic.
Interpretation Our short-term findings will inform key stakeholders and knowledge users to shape current and future pandemic responses. Additionally, this study provides a unique resource to study the long-term impacts of the pandemic as the CHILD Cohort Study continues.
Introduction
SARS-CoV-2 infection results in a broad range of clinical phenotypes, from asymptomatic infection to severe disease and death1,2. Pre-existing medical conditions, socioeconomic disadvantage, occupation, gender, and race/ethnicity have been associated with higher SARS-CoV-2 infection rate and disease severity in adults3–6. However, much of the biological variation in this new disease remains unexplained, and more research is needed to understand why children are less likely than adults to develop severe COVID-197–9. Identifying these divergent outcomes in adults and children will help inform prevention and treatment strategies for people of all ages10. Additionally, understanding the persistence and biology of antibody responses following infection or vaccination will help inform public health responses to the ongoing pandemic.
In an effort to control this pandemic, public health measures have varied across Canada both geographically and over time. COVID-19 vaccination and non-pharmaceutical interventions, such as masking and school closures, have helped slow the spread of COVID-19 in Canada and beyond3,11,12. However, these measures have had consequences to the economy, mental health, and emotional and physical wellbeing of family members. They may also amplify inequities experienced by marginalized and vulnerable populations12. It is therefore important to assess how pandemic control measures differentially affect the short and long-term physical and mental health of Canadian families.
The CHILD Cohort Study (www.childstudy.ca), an ongoing birth cohort of 3454 families, offers a unique opportunity to study COVID-19 as CHILD has collected a wealth of sociodemographic, health and biological data since 2009. The CHILD COVID-19 Add-On Study (Figure 1) will investigate (1) symptomatic and asymptomatic SARS-CoV-2 infection prevalence, transmission, and immunity; (2) predictors of SARS-CoV-2 infection susceptibility and severity; (3) prevalence and predictors of health and psychosocial impacts of the COVID-19 pandemic on CHILD families; and (4) individual and social determinants of COVID-19 vaccine uptake or hesitancy. Further, it will provide a lasting resource to study the long-term impacts of the pandemic as the CHILD Cohort Study continues.
Methods and Study Population
Study design and population
This is a prospective longitudinal study embedded in the existing CHILD cohort. CHILD is a general population cohort that recruited 3454 families (∼10,000 individuals) with children born in British Columbia, Alberta, Manitoba, and Ontario between 2009-12 (90.7% retention to date)13. Eligible participants for the COVID Add-On Study included all parents and children enrolled in the CHILD Cohort Study plus all other individuals living in the same household (n= 3032 eligible households) (Figure 2). This COVID Add-On Study involves (1) brief biweekly surveys about COVID-19 symptoms and testing; (2) quarterly questionnaires assessing COVID-19 exposure and vaccination status and pandemic-driven life changes; (3) in-home collection of blood for SARS-CoV-2 IgG serology, biomarker analysis and (optionally) genetic analysis, and stool for microbiome analysis.
Consent, recruitment, and retention
Eligible participants were invited to take part in this study during in-person CHILD Cohort Study clinic visits or by phone, video call or e-mail, between November 2020 and May 2021. E-mail invitations included a summary of the study, a YouTube video (https://www.youtube.com/watch?v=lEzbn7HYiQw) describing the study’ s purpose and participation requirements, and instructions on how to arrange a virtual consent appointment with research staff. Participants attending clinic visits were provided with paper consent forms. Otherwise, consent was obtained virtually during a videoconference appointment with study staff (2021 Zoom Video Communications, Inc.) using the web browser-based Research Electronic Data Capture (REDCap) consent module14,15. Child participant assent (as defined provincially by age) or consent was obtained in the same manner in the presence of their caregiver. Participants were invited to additionally provide consent for three optional activities: (1) whole genome sequencing (65% consented), (2) future undefined analyses on their biological samples (69%) and (3) analysis of previously collected biological samples for future unknown research studies (59%). To encourage retention, we provided gift cards ($25/household for completion of the baseline survey, and again for return of biological samples) and returned SARS-CoV-2 serology results to participants.
Recruited population and early pandemic experiences at enrolment
The final CHILD COVID-19 Add-On Study population (Table 1) included 5378 participants from 1462 households (mean 3.7 participants per household; IQR 3-4; range 1-12), of which 3848 were original CHILD participants (1431 mothers, 1015 fathers and 1402 children). The remaining 1530 participants were siblings (n=1427) or other household members (n=103). Almost half (48%) of eligible CHILD households consented to participate in the CHILD COVID-19 Add-On Study. A total of 370 (12% of eligible) households actively declined to participate, while the remainder were unresponsive (40%, n=1205). Compared to non-participating CHILD families, those participating in the COVID-19 Add On Study tended to have higher education and household income, and larger households (Table S1). Participants were distributed across the Manitoba (34%), Vancouver (27%), Toronto (22%) and Edmonton (17%) study sites. Among children enrolled (n=2802, 52% female) the mean age was 9 years (SD 2.7, range 0-17), while among adults (n=2576, 58% female), the mean age was 43 years (SD 6.5, range 18-85) (Figure 3). Participants predominantly identified as having European ancestral origins (77%) and the majority (68%) of adults had a university degree.
At enrollment, 28% of adults were essential workers (e.g., healthcare, delivery, store, security and building maintenance), ranging from 16% in Toronto to 39% in Manitoba. During the first wave of the pandemic, 45% of working adults moved to remote work, 9% lost their job (permanently or temporarily) and 35% accessed government supports (e.g., loan deferrals, personal or business income support). The majority of children (84%) experienced school closures during spring 2020 (range: 80-89% across study sites), of which 23% returned to in-person classes before the end of the academic year in June 2020 (ranging from 6% in Edmonton to 51% in Vancouver). Most children who experienced school closures were offered (92%) and attended (85% fully and 14% partially) online classes (Table 1).
Biweekly surveys
Study participants’ COVID-19 symptoms, exposure and diagnosis were captured through a biweekly symptom survey (Appendix 1). Beginning in December 2020, one designated participant per household was prompted biweekly by text message or e-mail (according to their preference) with three COVID-19 screening questions asking if anyone in their household had symptoms of, was suspected of having, or was tested for COVID-19. Participants responding ‘ yes’ to any of these questions were sent a follow-up COVID-19 symptom survey by e-mail to collect individual-level information on specific COVID-19 symptoms and testing, travel, and exposure history, as well as clinical or public health action taken after a positive COVID-19 test result. Completion rates for the biweekly surveys ranged from 70% in the Edmonton site to 88% in the Winnipeg site and generally were consistent over time.
Quarterly questionnaires
Questionnaires (Appendix 1) were delivered online using REDCap at enrolment and approximately every 3 months thereafter (Figure 2). They were adapted from other Canadian COVID-19 studies, and addressed the following topics: individual demographic characteristics, employment status, COVID-19 pandemic government support use, mental and physical health, school closures, adherence to non-pharmaceutical public health measures, screen time and use of technology for school/work or other purposes, COVID-19 symptoms, testing and diagnosis, travel history and COVID-19 vaccination perceptions and status. There were three versions of each questionnaire, designed for completion by children (about themselves), adults (about themselves), or parents/caregivers (about their children). Individuals able to provide consent on their own behalf were asked to complete the adult questionnaire. All remaining participants (i.e., children enrolled through assent or caregiver consent) were asked to complete the child questionnaire. Caregivers of participating children were also asked to complete a parent questionnaire for each child enrolled in their household. Completion rates for the quarterly questionnaires ranged from 85% (n=6287) at baseline to 44% (n=3248) at the final follow-up (Table 2). In general, the sociodemographic characteristics of participants who completed the final follow-up survey (51% of adults and 49% of children) did not differ much from those who did not. However, participants who did not complete the final survey were slightly more likely to be essential workers and have a lower level of formal education (Table S2).
In-home biological sample collection and SARS-CoV-2 serology
Blood and stool samples were collected twice (Spring and Fall/Winter 2021) using in-home sampling kits sent to each household along with a pre-paid return shipment box. Participants were asked to collect all samples within a 48-hour period of receipt. Sample kits were prepared by DaklaPack company (Moonachie, NJ, USA) and included all materials required to collect blood and stool, including an instructional pamphlet (Appendix 2), 2-Ply 70% alcohol swabs, 2”x2” 8-Ply sterile gauze sponges (VWR CA95041-740), bandages, a registration card and specimen bag containing a Desco Humidity Indicator Cards (VWR, 89131-360) and MiniPax absorbent desiccant packets (Sigma-Aldrich, Z163570). Sample packages were returned to the Clinical Research Laboratory and Biobank (CRLB, Hamilton, ON) by airmail. Collection rates for biological samples were 56% in the first wave and 57% in the second wave of collection (Table 2).
Blood Collection
Blood specimens were collected using the Dried Blood Spot (DBS) method and Mitra Blood Collection devices. DBS were collected using a Whatman 903 protein saver 5-spot card (VWR Int, Radnor, PA, USA). Returned sample bags containing DBS collection cards, desiccant pouches and humidity cards were sealed in a second polybag and stored at 4°C for SARS-CoV-2 serological analysis using automated chemiluminescent ELISAs to detect anti-spike and anti-nucleoprotein antibodies as described by Cholette F., et al. 202116. COVID-19 antigens and anti-hIgG#5-HRP fusion antibody were generously provided by Dr. Yves Durocher, National Research Council of Canada. Cutoffs for seropositivity used were based on False Discovery Rates (FDRs) in prepandemic cohorts of 2% for Spike and both 1% and 10% for Nucleoprotein. Preserved blood was also collected using the Mitra Clamshell Devices containing two samplers (Neoteryx, Torrance, CA, USA). Upon receipt, the clamshell casing was removed, samplers were loaded into a 96-autorack, placed into a polybag containing a desiccant pouch and stored at −80°C until further use. Metabolomic and genomic analyses are planned, pending further funding.
Stool Collection
Stool samples were collected by participants using two cotton tipped swabs. Fecal swabs were then suspended in a capped collection tube containing ethanol for transport. Upon receipt, the shafts of the fecal swabs were cut off and the specimens were cryopreserved. Microbiome analyses are planned, pending further funding.
Statistical analysis plan
Aim 1: Estimate SARS-CoV-2 infection, transmission, severity, and immunity
Prevalence and severity of infection will be estimated from self-reported biweekly reports, quarterly questionnaire testing information, and serological testing. Severity will be classified as asymptomatic, mild, or severe using WHO criteria19. Transmission will be assessed using multilevel modelling (by household and study site). Persistence of SARS-CoV-2-induced immunity will be determined from longitudinal serology testing for SARS-CoV-2 antibodies over two time frames (Spring and Fall 2021).
Aim 2: Identify predictors of SARS-CoV-2 infection susceptibility and severity
We will combine new data from the CHILD COVID-19 Add On Study with existing pre-pandemic CHILD data to predict SARS-CoV-2 infection susceptibility (incidence) and severity. We hypothesize that infection susceptibility will be associated with (a) physical interactions with (or distancing from) other individuals in the community during the pandemic, (b) sociodemographic characteristics including sex, age, occupation, socioeconomic status, and household size (c) pre-existing medical conditions including obesity and asthma, (d) neighbourhood characteristics including air pollution exposure, housing type, green and blue spaces, and (e) pre-pandemic immune biomarker and genetic profiles, viral infection history (including pre-existing coronavirus serology), respiratory health (wheezing, lung function), and health-related lifestyle factors (e.g., diet quality and physical activity). Associations will be tested in multivariate regression models with a three-category outcome (symptomatic, asymptomatic or no infection), random forest analysis, gradient boosting, recursive feature elimination and mutual information method. If sufficient cases are identified, we will also evaluate infection severity.
Aim 3: Understand the impact of COVID-19 pandemic on mental and physical health of Canadian families using a health equity lens
We will quantify prevalence of and changes between pre-pandemic and during-pandemic physical and mental health functioning (not directly related to SARS-CoV-2 infection). Prediction models, as described for Aim 2, will be used to identify factors that predict risk for (or protection against) poor pandemic-related mental and physical health functioning. We hypothesize that protective factors will include (a) maintaining social connections, physical activity, healthy eating behaviours, and adequate sleep during the pandemic, (b) higher pre-pandemic mental wellbeing, and (c) continued employment throughout the pandemic.
Integrated knowledge translation and participant engagement
The CHILD COVID-19 Add-On Study adopts an integrated knowledge translation approach. To accelerate the availability and translation of high quality, real-time evidence, we included key stakeholders on our team to develop the study and translate and disseminate results. Our team includes members of the CHILD Parent Advisory Committee and Knowledge Users from public health authorities at the national (Public Health Agency of Canada) and provincial levels (BC Centre for Disease Control, Alberta Health Services, Manitoba Shared Health, Public Health Ontario) who meet monthly with study investigators to share data in real-time and adapt procedures if necessary (e.g., modify symptom surveys, questionnaires, and serology testing methods) to ensure that our results can be rapidly translated into policy and practice. Study investigators also meet monthly with the Canadian Covid Immunity Task Force Pediatric Working Group to share experiences and expertise, develop harmonized protocols, and foster research collaborations. A Rapid Results website (https://childstudy.ca/covid-rapid-results/) was developed to facilitate rapid widespread translation of study results to participants and stakeholders. To maximize recruitment, retention and relevance to families, the CHILD Parent Advisory Committee was engaged to co-develop the study design, grant application, recruitment strategies and questionnaires.
In addition to traditional dissemination of results through open access publication in peer-reviewed journals, we will use our website (childstudy.ca/covid-rapid-results) and social media (Twitter) to rapidly disseminate time-sensitive findings that are relevant to stakeholders and knowledge users, including provincial public health organizations and non-profit organizations (e.g., Children First Canada). We will also engage the CHILD Knowledge Mobilization Stakeholder Advisory Committee, which includes stakeholders from government, industry, patient organizations, clinical societies, child health-focused organizations, parenting-focused communications platforms, and CHILD parents.
Ethics approval and consent to participate
This study was approved by Research ethics boards at the University of British Columbia (H20-02324), University of Alberta (Pro00102524), University of Manitoba (HS24250), The Hospital for Sick Children (1000071220) and McMaster University (1108).
Interpretation
Our study will provide timely data on SARS-CoV-2 infection and transmission dynamics, and the mental and physical health of Canadian families during the pandemic. Importantly, these new data will be linked to a wealth of existing data from the ongoing CHILD Cohort Study where, over more than a decade of participation, CHILD families have attended repeated clinical assessments; contributed longitudinal data on their health, environment, and lifestyle; and donated biological samples for genetic and biomarker analysis. This unique data resource will allow us to determine which individuals and families are particularly susceptible or resilient to COVID-19 and the indirect psychosocial impacts of the pandemic, and then identify risk and protective factors for these outcomes. This research will help us understand how the pandemic is disrupting social connections and health behaviours, how families are coping, and which families would benefit most from targeted social supports and programming. In addition, because it is nested within an ongoing longitudinal cohort, our study has the potential to investigate long-term sequelae of COVID-19 (Long COVID).
Limitations and pandemic-related challenges
While it offers a powerful opportunity to leverage existing research infrastructure and pre-pandemic data, nesting our study within the ongoing CHILD Cohort Study also presents challenges. For example, participant burden is a paramount concern and must be considered within the context of the ongoing CHILD Cohort Study. Additionally, generalizability may be limited by selection bias because socioeconomic status tends to be higher among CHILD families than the general population. Other study limitations are related to unanticipated challenges encountered during the pandemic (Figure 4). For example, we were unable to collect data during a critical period of the pandemic (summer 2020) because ethical approvals were delayed by the introduction of many novel study elements (e.g., virtual consent by video conference and in-home sample collection). Pandemic-driven supply chain disruptions made acquiring biological sample kit components (e.g., gauze, bandages) exceedingly difficult, leading to delays in sample collection. Despite being used in the USA for serology testing, the Mitra Clamshell devices were not approved by Health Canada in time for study deployment. Standard DBS methods were used instead, requiring a more painful finger prick and larger blood volume which negatively impacted retention. The frequent biweekly questionnaires and lengthy adult and parent quarterly questionnaires created a large burden on the designated household participant responsible for providing responses for themselves and all household members. Collectively, the high burden placed on participants led to study withdrawal in a subset of families.
Conclusion
To our knowledge, there is no other multi-site pediatric cohort with rich longitudinal data and recent pre-pandemic biosamples available to investigate how current and pre-pandemic health status, immune phenotypes and biomarkers can interactively predict susceptibility and resilience to COVID-19 and the psychosocial impacts of the pandemic. The CHILD Cohort offers a unique and powerful opportunity to study the clinical features and long-term sequelae of COVID-19, assess viral transmission within households, understand COVID-19 vaccine uptake/hesitancy, and investigate the psychosocial impact of the pandemic and its management among Canadian children and their families.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Declarations
Authors’ contributions
RA contributed to conceptualization, writing the original draft, formal analysis and reviewing and editing the final version. LL contributed to conceptualization, writing the original draft, project administration and supervision, formal analysis, and reviewing and editing the final version. MER contributed to formal analysis and reviewing the final version. MM contributed to writing the original draft and editing and reviewing the final version. AD contributed to conceptualization, project administration, and data curation. TF contributed to project administration and data curation. GW and SG contributed to data curation and formal analysis. FB contributed to conceptualization, funding acquisition, data curation, formal analysis and reviewing and editing the final version. ML, CA, YG and MP contributed to serological analysis, editing and reviewing the final version. SB, DM, KW, JB, and DP, contributed to conceptualization, funding acquisition, and reviewing and editing the final version. ES, TJM, TES, PJM and PS contributed to conceptualization, funding acquisition, and reviewing and editing the final version. EC and LR contributed to questionnaire review and revision, formal analysis, reviewing, and editing the final version. NR contributed to conceptualization, funding acquisition, project administration and reviewing the final version. MBA contributed to conceptualization, writing the original draft, funding acquisition, project administration and supervision, formal analysis, methodology and reviewing and editing the final version.
Funding
This work was supported by funding from the Canadian Institutes of Health Research and the Canadian COVID-19 Immunity Task Force [VR5-172658] and Research Manitoba [4494]. Core funding for the CHILD Cohort Study was provided by the Canadian Institutes of Health Research [CIHR; AEC-85761, PJT-148484, FDN-159935, and EC1-144621], the Allergy, Genes and Environment Network of Centres of Excellence (AllerGen NCE) [12CHILD], BC Children’ s Hospital Foundation, Don & Debbie Morrison, and Genome Canada/Genome BC [274CHI]. This research was supported, in part, by the Canada Research Chairs program: MBA holds a Tier 2 Canada Research Chair in the Developmental Origins of Health and Disease; SET holds a Tier 1 Canada Research Chair in Pediatric Precision Health; PS holds Tier 1 Canada Research Chair in Pediatric Asthma & Lung Health EC is supported by a Social Science and Humanities Research Council Postdoctoral Fellowship. FSLB is an SFU Distinguished Professor. YG is supported by a Frederick Banting and Charles Best CGS-D from the Canadian Institutes of Health Research [FBD-181487]. Production of COVID-19 reagents was financially supported by NRC’ s Pandemic Response Challenge Program. The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. In alignment with the call from the Canadian Chief Science Advisors, this COVID-19 related publication will be open access.
Data availability
Existing CHILD researchers and CHILD-COVID Knowledge Users will be given rapid access to study data on request. New researchers interested in developing or collaborating on a project using CHILD data are encouraged to contact the study’ s National Coordinating Centre for a formal request. Details for data request and access are outlined on the CHILD website: https://childstudy.ca/for-researchers/study-data/.
Competing interests
The authors declare that they have no competing interests.
Supplementary Material
Appendix 1 – CHILD COVID-19 Add-On Study Data Collection Tools
Appendix 2 - CHILD COVID-19 Add-On Study Sample Collection Instructions
Acknowledgements
We are grateful to all the families who took part in this CHILD COVID-19 Add-on Study and the entire CHILD Study team, which includes study site coordinators, research assistants, nurses, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, and receptionists at the following institutions: McMaster University, University of Manitoba, University of Alberta, SickKids, and University of British Columbia. We acknowledge Jay Onysko (Public Health Agency of Canada) who served on the CHILD COVID-19 Add-on Study Knowledge User Committee. We thank the main CHILD Cohort Study participant families for their dedication and commitment to advancing health research.
Abbreviations
- ACE2
- Angiotensin-converting Enzyme 2
- BC
- British Columbia
- CANCOGEN
- Canadian COVID Genomics Network
- CANUE
- Canadian Urban Environmental Health Research Consortium
- CHILD
- Canadian Healthy Infant Longitudinal Development
- CINECA
- Common Infrastructure for National Cohorts in Europe, Canada, and Africa
- COVID-19
- Coronavirus disease 2019
- CRISIS
- CoRonavIruS Health Impact Survey
- DBS
- Dried Blood Spots
- ELISA
- Enzyme-linked Immunosorbent Assay
- IgG
- Immunoglobulin G
- NCC
- National Coordinating Centre
- NGOs
- Non-Governmental Organizations
- REDCap
- Research Electronic Data Capture
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus 2
- SNP
- Single Nucleotide Polymorphisms
- UNESCO
- United Nations Educational, Scientific and Cultural Organization
- UNICEF
- United Nations Children’ s Fund
- WHO
- World Health Organization